title: Effect of statins on atherogenic serum amyloid A and α1-antitrypsin low-density lipoprotein complexes.
abstract: OBJECTIVE
  HMG-CoA reductase inhibitors, also termed statins, are used to reduce the risk of coronary artery disease. Two oxidatively modified low-density lipoprotein (LDL) complexes, serum amyloid A-LDL (SAA-LDL) and α1-antitrypsin-LDL (AT-LDL), serve as atherosclerotic, inflammatory, and cardiovascular risk markers. In this study, we examined the effects of hydrophilic rosuvastatin (RSV) and lipophilic pitavastatin (PTV) on these markers in patients with hypercholesterolemia.
  
  
  METHODS
  The present study was a sub-analysis of our previous STAT-LVDF study. The subjects were treated with RSV or PTV for 24weeks. Changes in glucose-lipid metabolism, serum levels of SAA-LDL and AT-LDL, and C-reactive protein (CRP) level were assessed.
  
  
  RESULTS
  In total, 53 patients were analyzed in the present study. RSV and PTV significantly decreased SAA-LDL (RSV: p=0.003, PTV: p=0.012) and AT-LDL levels (RSV: p=0.013, PTV: p=0.037). Changes in SAA-LDL level were significantly and positively correlated with those in CRP in both the RSV (r=0.549, p=0.003) and PTV (r=0.576, p=0.004) groups. Moreover, a positive correlation between changes of SAA-LDL levels and those of HbA1c levels was observed in the PTV group (r=0.442, p=0.030) but not in the RSV group (r=-0.100, p=0.611).
  
  
  CONCLUSIONS
  Both hydrophilic rosuvastatin and lipophilic pitavastatin reduce serum levels of atherosclerotic and inflammatory markers. These findings also indicate differential effects of RSV and PTV on glucose tolerance.
authors.affiliation: Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan; Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Miyazaki
authors.affiliation: Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan; Shizuoka General Hospital, Shizuoka, Japan; Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
authors.forename: Yasufumi
authors.initials: Y
authors.lastname: Katanasaka
authors.affiliation: Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan; Shizuoka General Hospital, Shizuoka, Japan; Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Sunagawa
authors.affiliation: Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan; Shizuoka Saiseikai General Hospital, Shizuoka, Japan.
authors.forename: Sae
authors.initials: S
authors.lastname: Hirano-Sunagawa
authors.affiliation: Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan; Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
authors.forename: Masafumi
authors.initials: M
authors.lastname: Funamoto
authors.affiliation: Shizuoka General Hospital, Shizuoka, Japan.
authors.forename: Eriko
authors.initials: E
authors.lastname: Morimoto
authors.affiliation: Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
authors.forename: Maki
authors.initials: M
authors.lastname: Komiyama
authors.affiliation: Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Shimatsu
authors.affiliation: Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
authors.forename: Noriko
authors.initials: N
authors.lastname: Satoh-Asahara
authors.affiliation: Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
authors.forename: Hajime
authors.initials: H
authors.lastname: Yamakage
authors.affiliation: Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Wada
authors.affiliation: Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
authors.forename: Koji
authors.initials: K
authors.lastname: Hasegawa
authors.affiliation: Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan; Shizuoka General Hospital, Shizuoka, Japan; Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan. Electronic address: morimoto@u-shizuoka-ken.ac.jp.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Morimoto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D050197:Atherosclerosis / Q000097:blood* / Q000188:drug therapy*; D015415:Biomarkers / Q000097:blood; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D008077:Lipoproteins, LDL / Q000037:antagonists & inhibitors / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use; D000068718:Rosuvastatin Calcium / Q000494:pharmacology / Q000627:therapeutic use; D000685:Serum Amyloid A Protein / Q000037:antagonists & inhibitors / Q000378:metabolism*; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000188:drug therapy; D000515:alpha 1-Antitrypsin / Q000097:blood*
chemical_list: D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008077:Lipoproteins, LDL; D011804:Quinolines; D000685:Serum Amyloid A Protein; D000515:alpha 1-Antitrypsin; D000068718:Rosuvastatin Calcium; C108475:pitavastatin
keywords: AT-LDL; Dyslipidemia; Pitavastatin; Rosuvastatin; SAA-LDL; Statins